These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 2381997)

  • 1. Generation of lymphokine-activated killer (LAK) cells and possible implications in autologous bone marrow transplantation--a preliminary report.
    Tzeng CH; Chuang MW; Wang SY; Hsieh RK; Liu CJ; Fan S; Chen PM
    Proc Natl Sci Counc Repub China B; 1990 Jan; 14(1):47-53. PubMed ID: 2381997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
    Long GS; Cramer DV; Harnaha JB; Hiserodt JC
    Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro.
    van den Brink MR; Voogt PJ; Marijt WA; van Luxemburg-Heys SA; van Rood JJ; Brand A
    Blood; 1989 Jul; 74(1):354-60. PubMed ID: 2787676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphokine-activated killer (LAK) cell purging of bone marrow.
    Cramer DV; Long GS
    Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.
    Oshimi K; Oshimi Y; Akutsu M; Takei Y; Saito H; Okada M; Mizoguchi H
    Blood; 1986 Oct; 68(4):938-48. PubMed ID: 3489494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose subcutaneous interleukin-2 after autologous transplantation generates sustained in vivo natural killer cell activity.
    Miller JS; Tessmer-Tuck J; Pierson BA; Weisdorf D; McGlave P; Blazar BR; Katsanis E; Verfaillie C; Lebkowski J; Radford J; Burns LJ
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):34-44. PubMed ID: 9209739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG; Deal H; Reid D; Eaves CJ
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphokine-activated killer cell purging of leukemia cells from bone marrow prior to syngeneic transplantation.
    Long GS; Hiserodt JC; Harnaha JB; Cramer DV
    Transplantation; 1988 Sep; 46(3):433-8. PubMed ID: 2901797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
    Scheffold C; Brandt K; Johnston V; Lefterova P; Degen B; Schöntube M; Huhn D; Neubauer A; Schmidt-Wolf IG
    Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia.
    Beaujean F; Bernaudin F; Kuentz M; Lemerle S; Cordonnier C; Le Forestier C; Reinert P; Duedari N; Brandely M; Vernant JP
    Bone Marrow Transplant; 1995 May; 15(5):691-6. PubMed ID: 7670397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective purging by human interleukin-2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells.
    Gambacorti-Passerini C; Rivoltini L; Fizzotti M; Rodolfo M; Sensi ML; Castelli C; Orazi A; Polli N; Bregni M; Siena S
    Br J Haematol; 1991 Jun; 78(2):197-205. PubMed ID: 2064957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.